Vbi Vaccines Stock Current Valuation
| VBIVQ Stock | 0.0005 0.00 0.000004% |
Valuation analysis of VBI Vaccines helps investors to measure VBI Vaccines' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, VBI Vaccines' Begin Period Cash Flow is relatively stable compared to the past year. As of 12/26/2024, Other Non Cash Items is likely to grow to about 630.4 K, while Free Cash Flow is likely to drop (64.8 M).
Overvalued
Today
Please note that VBI Vaccines' price fluctuation is out of control at this time. Calculation of the real value of VBI Vaccines is based on 3 months time horizon. Increasing VBI Vaccines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
VBI Vaccines' intrinsic value may or may not be the same as its current market price of 0.0005, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.0E-4 | Real 4.8E-4 | Hype 5.21E-4 | Naive 0.001688 |
The intrinsic value of VBI Vaccines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VBI Vaccines' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of VBI Vaccines helps investors to forecast how VBI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VBI Vaccines more accurately as focusing exclusively on VBI Vaccines' fundamentals will not take into account other important factors: VBI Vaccines Company Current Valuation Analysis
VBI Vaccines' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, VBI Vaccines has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
VBI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in current valuation category among its peers.
VBI Fundamentals
| Revenue | 8.68 M | ||||
| Net Income | (92.84 M) | ||||
| Total Debt | 50.77 M | ||||
| Cash Flow From Operations | (60.88 M) | ||||
| Number Of Employees | 131 | ||||
| Total Asset | 86.95 M | ||||
| Retained Earnings | (582.45 M) | ||||
| Working Capital | (39.51 M) | ||||
| Net Asset | 86.95 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with VBI Vaccines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VBI Vaccines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VBI Vaccines will appreciate offsetting losses from the drop in the long position's value.Moving together with VBI Stock
Moving against VBI Stock
| 0.53 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.48 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.44 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.39 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.37 | UPB | Upstream Bio, | PairCorr |
The ability to find closely correlated positions to VBI Vaccines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VBI Vaccines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VBI Vaccines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VBI Vaccines to buy it.
The correlation of VBI Vaccines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VBI Vaccines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VBI Vaccines moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VBI Vaccines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for VBI Stock Analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.